NASDAQ:BTCY Biotricity (BTCY) Stock Price, News & Analysis → Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad) Free BTCY Stock Alerts $1.12 +0.03 (+2.75%) (As of 05/14/2024 ET) Add Compare Share Share Today's Range$1.09▼$1.2050-Day Range$0.95▼$1.6352-Week Range$0.70▼$4.37Volume39,307 shsAverage Volume81,280 shsMarket Capitalization$10.55 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Biotricity alerts: Email Address Biotricity MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish7.35% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.91Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.55) to ($0.43) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.40 out of 5 starsMedical Sector2652nd out of 2,771 stocksSurgical & Medical Instruments Industry286th out of 300 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Biotricity.Read more about Biotricity's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.35% of the float of Biotricity has been sold short.Short Interest Ratio / Days to CoverBiotricity has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Biotricity has recently increased by 30.78%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBiotricity does not currently pay a dividend.Dividend GrowthBiotricity does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BTCY. Previous Next 3.8 News and Social Media Coverage News SentimentBiotricity has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Biotricity this week, compared to 0 articles on an average week.Search Interest5 people have searched for BTCY on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat Follows2 people have added Biotricity to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Biotricity insiders have not sold or bought any company stock.Percentage Held by Insiders20.46% of the stock of Biotricity is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 3.89% of the stock of Biotricity is held by institutions.Read more about Biotricity's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Biotricity are expected to grow in the coming year, from ($1.55) to ($0.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biotricity is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biotricity is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Biotricity's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingREAD THIS – If You Missed Out On The AI BoomAdam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”Click on Adam's shiny forehead for more details. About Biotricity Stock (NASDAQ:BTCY)Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.Read More BTCY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BTCY Stock News HeadlinesApril 19, 2024 | finanznachrichten.deBiotricity, Inc.: Biotricity Launches Major Cardiac Monitoring Pilot Program in a Hospital System Comprised of 9 Hospitals and 10 ClinicsApril 17, 2024 | investing.comBiotricity pilots cardiac tech at major hospital networkApril 16, 2024 | finanznachrichten.deBiotricity, Inc.: Biotricity Launches Cardiac Monitoring Pilot Program with Major Hospital NetworkMarch 28, 2024 | finanznachrichten.deLOBO EV and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TVMarch 2, 2024 | finance.yahoo.comBiotricity, Inc. (BTCY) Interactive Stock Chart - Yahoo FinanceFebruary 29, 2024 | finanznachrichten.deBiotricity, Inc.: Biotricity Receives Health Canada Clearance for BiotresFebruary 22, 2024 | finance.yahoo.comBiotricity, Inc. (NASDAQ:BTCY) Q3 2024 Earnings Call TranscriptFebruary 21, 2024 | benzinga.comBiotricity Stock (NASDAQ:BTCY) Dividends: History, Yield and DatesFebruary 20, 2024 | finance.yahoo.comBiotricity Inc. (BTCY) Reports Q3 Loss, Misses Revenue EstimatesFebruary 20, 2024 | finanznachrichten.deBiotricity, Inc.: Biotricity to Host Third Quarter Fiscal Year 2024 Financial Results and Business Update Call on February 21stNovember 16, 2023 | finance.yahoo.comBiotricity, Inc. (NASDAQ:BTCY) Q2 2024 Earnings Call TranscriptNovember 14, 2023 | benzinga.comBiotricity Delivers Record Margins and Double Digit Year-Over-Year Sales Growth for Second Quarter of Fiscal Year 2024November 10, 2023 | finance.yahoo.comBiotricity to Host Second Quarter Fiscal Year 2024 Financial Results and Business Update Call on November 14thOctober 3, 2023 | finanznachrichten.deBiotricity, Inc.: Biotricity Announces Patient Filing for Cutting-Edge Biotres DeviceSeptember 13, 2023 | finance.yahoo.comBiotricity Unveils a New Digital Presence, Highlighting its Expanding Technology Portfolio and Cutting-Edge InnovationsAugust 30, 2023 | finanznachrichten.deBiotricity, Inc.: Biotricity Achieves $14 Million Revenue Run Rate in August 2023August 30, 2023 | finance.yahoo.comBiotricity Achieves $14 Million Revenue Run Rate in August 2023See More Headlines Receive BTCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biotricity and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/20/2024Today5/14/2024Next Earnings (Estimated)7/04/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:BTCY CUSIPN/A CIK1630113 Webwww.biotricity.com Phone(800) 590-4155FaxN/AEmployees55Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.3899) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,660,000.00 Net Margins-125.43% Pretax Margin-125.43% Return on EquityN/A Return on Assets-233.67% Debt Debt-to-Equity RatioN/A Current Ratio0.21 Quick Ratio0.10 Sales & Book Value Annual Sales$9.64 million Price / Sales1.12 Cash FlowN/A Price / Cash FlowN/A Book Value($2.27) per share Price / Book-0.51Miscellaneous Outstanding Shares9,420,000Free Float7,493,000Market Cap$10.84 million OptionableOptionable Beta1.54 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Waqaas Al-Siddiq Ph.D. (Age 39)Founder, President, CEO & Chairman Comp: $732kMr. S. John Ayanoglou (Age 57)Chief Financial Officer Comp: $305.75kMr. Andy WongVice President of OperationsDr. George N. NikopoulosDirector of Business DevelopmentMr. Matt ZabelVice President of Sales & StrategyMr. Amir AliChief Development OfficerMore ExecutivesKey CompetitorsPetVivoNASDAQ:PETVMicrobot MedicalNASDAQ:MBOTPlus TherapeuticsNASDAQ:PSTVSTRATA Skin SciencesNASDAQ:SSKNNEXGELNASDAQ:NXGLView All CompetitorsInstitutional OwnershipAdvisor Resource CouncilBought 79,070 shares on 4/19/2024Ownership: 0.839%View All Institutional Transactions BTCY Stock Analysis - Frequently Asked Questions Should I buy or sell Biotricity stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biotricity in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" BTCY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BTCY, but not buy additional shares or sell existing shares. View BTCY analyst ratings or view top-rated stocks. How have BTCY shares performed in 2024? Biotricity's stock was trading at $1.15 at the start of the year. Since then, BTCY shares have decreased by 2.6% and is now trading at $1.12. View the best growth stocks for 2024 here. When is Biotricity's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, July 4th 2024. View our BTCY earnings forecast. How were Biotricity's earnings last quarter? Biotricity, Inc. (NASDAQ:BTCY) posted its earnings results on Tuesday, February, 20th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.07. The company earned $2.97 million during the quarter, compared to the consensus estimate of $3 million. When did Biotricity IPO? Biotricity (BTCY) raised $15 million in an initial public offering on Thursday, August 26th 2021. The company issued 5,000,000 shares at $3.00 per share. H.C. Wainwright & Co. served as the underwriter for the IPO. Who are Biotricity's major shareholders? Biotricity's stock is owned by a number of retail and institutional investors. Top institutional investors include Advisor Resource Council (0.84%) and Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of Biotricity? Shares of BTCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BTCY) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersDid Intel Just Dethrone Nvidia?Chaikin AnalyticsCharles Payne Demystifies OptionsUnstoppable ProsperityRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressElon to Transform U.S. Economy? Porter & CompanyThe only AI company you should be looking atBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biotricity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.